Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer withdraws sickle cell drug Oxbryta
FDA alerts patients about Pfizer's Oxbryta withdrawal
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's sickle cell disease treatment Oxbryta.
What the withdrawal of its sickle cell drug means for Pfizer, patients, and the FDA
Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and scrambling for ways to notify their patients about a drug that has long divided the community.
Pfizer withdraws sickle cell disease drug Oxbryta amid safety concerns
The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and halted clinical trials of the drug as data indicate a high risk of severe adverse events.
12h
on MSN
Slow progress on Pfizer's plan to sell drugs to low-income nations at not-for-profit price, says CEO
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
12h
Can Pfizer Stock Rise 2x To $60?
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
1d
Pfizer yanks sickle-cell treatment worldwide after possible link to deaths
Pfizer Inc. said late Wednesday it was withdrawing a sickle-cell drug from markets worldwide and discontinuing clinical ...
11h
Pfizer withdraws sickle cell disease treatment on risk of complication, death
U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...
14h
Pfizer’s Stock Faces Challenges as Oxbryta Recall Impacts Drug Pipeline and Financial Projections
Pfizer (PFE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal ...
labiotech
1d
How Pfizer’s decision in the ’90s cost them a stronghold in the GLP-1 market
Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...
1d
on MSN
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...
2d
on MSN
Pfizer Inc. (PFE): Why Are Street Analysts Bullish On This Wide Moat Stock Now?
We recently compiled a list of the 8 Best Wide Moat Stocks to Buy According to Analysts. In this article, we are going to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
sickle cell drug
Oxbryta
COVID
BioNTech
vaccine
Feedback